Specific antigen in serum of patients with colon carcinoma
about
Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosidesGlycosylation-Based Serum Biomarkers for Cancer Diagnostics and PrognosticsThe clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updatesPotential prognostic, diagnostic and therapeutic markers for human gastric cancerAntibodies: At The Nexus of Antigens and Cancer VaccinesNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesBiomarkers in pancreatic adenocarcinoma: current perspectivesTargeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approachFabrication of gold nanoparticles for targeted therapy in pancreatic cancer.A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancerDevelopments in serologic detection of human pancreatic adenocarcinoma.Remembrances of Hilary Koprowski from a Surgeon's Perspective.Boronic acid functionalized peptidyl synthetic lectins: combinatorial library design, peptide sequencing, and selective glycoprotein recognition.Proteomic approaches to cancer biomarkers.Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma.Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies.Immunohistochemical Cal9-9 in primary colonic polyps and polyps synchronous with colorectal cancerMarkedly elevated CA19-9 associated with benign ovarian cyst and ascites.Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies.Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma.Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro.Protein biomarkers of ovarian cancer: the forest and the treesThe prognostic and predictive value of serum CA19.9 in pancreatic cancerCarbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinomaPostoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinomaCarbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scatteringCA 19-9 as a serum marker in urothelial carcinoma.Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.Advances in biomarker research for pancreatic cancer.Expression of α2,6-sialic acid-containing and Lewis-active glycolipids in several types of human ovarian carcinomas.Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours.Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancerStrategies for discovering novel pancreatic cancer biomarkers.CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
P2860
Q24298919-5245A330-174E-45CA-8585-A215104CC413Q26778227-E24BCDE6-2F37-4908-B8D3-7EB591725541Q26865015-E5CB54DE-8D4C-4285-AA73-45154E7CDAC2Q26866200-77149823-8678-4E14-98D0-B5C661131FF2Q27001058-B975E299-24E9-4F88-BC11-C7B5FEC04490Q27004292-8CEC2750-6E7F-4E38-BA0F-C8DEBA3FEF34Q28072309-316A4F04-A002-4A1B-9A96-31AAC657AA84Q28481264-4CBC520E-4CF0-42A7-93DE-CFCA209BE801Q33684453-C9233F22-C889-46C2-A796-953891B5843BQ33728198-FE68C70A-C6C7-46FE-8FBC-B4E9150A93BAQ33752171-4BCA3F23-E382-4BE7-8B90-CCBC3D494177Q33788898-303A5D8D-AE68-49E5-AD99-F85448D460F3Q33846322-3A105672-DDD8-45EA-AFDB-32013A7B1D91Q33864906-97FD4800-0B5F-4EEE-9632-2EB48BDFFA8BQ34293740-E5B00CC1-0C3F-4F26-AB57-9DED4B3D3A2BQ34519921-478D97FA-911C-4172-987F-AE2A20EBFE4AQ34527381-92DCCED9-342E-438C-9D4B-87E2C4E9DD07Q34536365-7548218C-DFE2-4967-8AA7-F85D29FC7687Q34540356-F851EC94-2D95-4423-8D64-85CC215C5E66Q34548390-D188E698-3C0B-4D8C-9524-AC8B95145109Q34568471-640A6435-EB12-46DE-BA18-2D252BA67A1AQ34614931-A22A161C-F5DA-4B72-8295-273320121DA0Q34622126-21CBBE66-054F-4549-8073-6C63DDC4EC60Q34634143-D8679435-2F36-4387-808E-EF80768372CCQ34635104-591DFEDE-F550-486B-B559-DC3DB29D8282Q34665177-E15E9FCD-8305-4851-A214-9B075FF46C71Q34732888-FF65ABF9-D0A8-446F-9180-C1D149449F90Q35089310-F0CD758D-DB79-48AD-984D-34F323E6D4C4Q35375731-A8F82E61-84E4-416F-957A-50321E2ABF50Q35860052-1071554B-B6B2-4EB5-B1E8-DD39FB82C4AAQ35970605-2B4A3C7A-DB19-4900-9101-A611D2861B70Q36025215-234A68AF-3BE3-4872-A00E-794270857A3DQ36126609-3187A483-EAFB-41A2-A563-893EFBCB0980Q36142404-0E379D0C-E67A-4536-A732-A1ADE898532EQ36201697-F07905B3-C4C0-401C-BF1B-6437CF164312Q36262320-576F0670-32BE-4D31-A7D1-72C401D70C17Q36292676-83461E99-D577-47E5-8EDF-E8C692FD1F21Q36467207-BE603B46-7601-4B97-ACBB-955980D02850Q36579311-9EF68EE7-00B5-421C-BDE2-26FA9E1C0F86Q36716676-2D45AC54-2563-463B-A61E-A0975800DE3C
P2860
Specific antigen in serum of patients with colon carcinoma
description
1981 nî lūn-bûn
@nan
1981 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Specific antigen in serum of patients with colon carcinoma
@ast
Specific antigen in serum of patients with colon carcinoma
@en
Specific antigen in serum of patients with colon carcinoma
@nl
type
label
Specific antigen in serum of patients with colon carcinoma
@ast
Specific antigen in serum of patients with colon carcinoma
@en
Specific antigen in serum of patients with colon carcinoma
@nl
prefLabel
Specific antigen in serum of patients with colon carcinoma
@ast
Specific antigen in serum of patients with colon carcinoma
@en
Specific antigen in serum of patients with colon carcinoma
@nl
P2093
P3181
P356
P1433
P1476
Specific antigen in serum of patients with colon carcinoma
@en
P2093
H Koprowski
Z Steplewski
P3181
P356
10.1126/SCIENCE.6163212
P407
P577
1981-04-03T00:00:00Z